A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of Subjects With Active Crohn’s Disease Bruce Yacyshyn, William Y. Chey, Mark K. Wedel, Rosie Z. Yu, David Paul, Emil Chuang Clinical Gastroenterology and Hepatology Volume 5, Issue 2, Pages 215-220 (February 2007) DOI: 10.1016/j.cgh.2006.11.001 Copyright © 2007 AGA Institute Terms and Conditions
Figure 1 Relationship between CRP, CumAUC, a measure of exposure to study drug, and probability of achieving clinical remission in subjects who received alicaforsen. Black line represents CRP = 2.0. Clinical Gastroenterology and Hepatology 2007 5, 215-220DOI: (10.1016/j.cgh.2006.11.001) Copyright © 2007 AGA Institute Terms and Conditions